Psychedelic microdosing

Psychedelic microdosing is the practice of consuming sub-perceptual (unnoticeable) amounts of a psychedelic substance, such as LSD or psilocybin mushrooms, typically for a range of purported benefits such as improved mood, productivity, or creativity. The practice has gained popularity in recent years, particularly within the tech industry and among professionals seeking a competitive edge in creativity and productivity.

History

The concept of microdosing has been around for a long time, but it gained significant attention in the 21st century. The term "microdosing" was popularized by James Fadiman, a psychologist and researcher who has conducted extensive studies on psychedelics.

Methodology

Psychedelic microdosing involves taking about 1/10th to 1/20th of a typical recreational dose of a psychedelic substance. This is usually done once every three days, following a schedule known as the "Fadiman Protocol". The doses are small enough to not cause hallucinations or other typical effects associated with these substances, but are believed to affect cognition and mood.

Effects and Research

Research into the effects of psychedelic microdosing is still in its early stages. Preliminary studies and anecdotal reports suggest potential benefits including enhanced creativity, increased energy, improved focus, and better relational skills. However, more rigorous scientific research is needed to confirm these effects and understand potential risks and long-term effects.

Legal Status

The legal status of psychedelic microdosing varies by country and depends on the substance being used. In many countries, including the United States, LSD and psilocybin are classified as Schedule I drugs under the Controlled Substances Act, making them illegal to manufacture, distribute, or possess.

See Also

• Psychedelic therapy
• Psychedelic drug
• James Fadiman
• Controlled Substances Act

References

<references />

   This article is a medical stub. You can help WikiMD by expanding it!